Predicted to enable enzyme binding activity. Predicted to be involved in positive regulation of apoptotic process and somatic diversification of immunoglobulins. Predicted to be located in centrosome; cytosol; and nucleoplasm. Predicted to be part of Prp19 complex and spliceosomal complex. Human ortholog(s) of this gene implicated in colorectal cancer; morbid obesity; and primary immunodeficiency disease. Orthologous to human CTNNBL1 (catenin beta like 1); PARTICIPATES IN spliceosome pathway; INTERACTS WITH 17alpha-ethynylestradiol; 17beta-estradiol; 2,4-dinitrotoluene.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTNNBL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTNNBL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTNNBL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTNNBL1 mRNA
[perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of CTNNBL1 mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of CTNNBL1 mRNA
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of CTNNBL1 protein